BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1587 related articles for article (PubMed ID: 31424364)

  • 21. Circ_0007841 knockdown confers cisplatin sensitivity to ovarian cancer cells by down-regulation of NFIB expression in a miR-532-5p-dependent manner.
    Gao Y; Huang Y
    J Chemother; 2023 Apr; 35(2):117-130. PubMed ID: 35380509
    [TBL] [Abstract][Full Text] [Related]  

  • 22. MiR-31 regulates the cisplatin resistance by targeting Src in gallbladder cancer.
    Li M; Chen W; Zhang H; Zhang Y; Ke F; Wu X; Zhang Y; Weng M; Liu Y; Gong W
    Oncotarget; 2016 Dec; 7(50):83060-83070. PubMed ID: 27825112
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Exosomes Serve as Nanoparticles to Deliver Anti-miR-214 to Reverse Chemoresistance to Cisplatin in Gastric Cancer.
    Wang X; Zhang H; Bai M; Ning T; Ge S; Deng T; Liu R; Zhang L; Ying G; Ba Y
    Mol Ther; 2018 Mar; 26(3):774-783. PubMed ID: 29456019
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Exosomal microRNA-588 from M2 polarized macrophages contributes to cisplatin resistance of gastric cancer cells.
    Cui HY; Rong JS; Chen J; Guo J; Zhu JQ; Ruan M; Zuo RR; Zhang SS; Qi JM; Zhang BH
    World J Gastroenterol; 2021 Sep; 27(36):6079-6092. PubMed ID: 34629821
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cancer-Derived Exosomal miR-651 as a Diagnostic Marker Restrains Cisplatin Resistance and Directly Targets ATG3 for Cervical Cancer.
    Zhu X; Long L; Xiao H; He X
    Dis Markers; 2021; 2021():1544784. PubMed ID: 34567283
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Evaluation of exosomal miR-9 and miR-155 targeting PTEN and DUSP14 in highly metastatic breast cancer and their effect on low metastatic cells.
    Kia V; Paryan M; Mortazavi Y; Biglari A; Mohammadi-Yeganeh S
    J Cell Biochem; 2019 Apr; 120(4):5666-5676. PubMed ID: 30335891
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Exosomal microRNA-107 reverses chemotherapeutic drug resistance of gastric cancer cells through HMGA2/mTOR/P-gp pathway.
    Jiang L; Zhang Y; Guo L; Liu C; Wang P; Ren W
    BMC Cancer; 2021 Dec; 21(1):1290. PubMed ID: 34856955
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Exosomal miR-500a-5p derived from cancer-associated fibroblasts promotes breast cancer cell proliferation and metastasis through targeting USP28.
    Chen B; Sang Y; Song X; Zhang D; Wang L; Zhao W; Liang Y; Zhang N; Yang Q
    Theranostics; 2021; 11(8):3932-3947. PubMed ID: 33664871
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Adipose Mesenchymal Stem Cell-Derived Exosomal microRNA-1236 Reduces Resistance of Breast Cancer Cells to Cisplatin by Suppressing SLC9A1 and the Wnt/β-Catenin Signaling.
    Jia Z; Zhu H; Sun H; Hua Y; Zhang G; Jiang J; Wang X
    Cancer Manag Res; 2020; 12():8733-8744. PubMed ID: 33061571
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Exosomal release of microRNA-454 by breast cancer cells sustains biological properties of cancer stem cells via the PRRT2/Wnt axis in ovarian cancer.
    Wang L; He M; Fu L; Jin Y
    Life Sci; 2020 Sep; 257():118024. PubMed ID: 32598931
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Long non-coding RNA CASC2 enhances cisplatin sensitivity in oral squamous cell cancer cells by the miR-31-5p/KANK1 axis.
    Wang J; Jia J; Zhou L
    Neoplasma; 2020 Nov; 67(6):1279-1292. PubMed ID: 32787433
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Exosomal transfer of miR-106a-5p contributes to cisplatin resistance and tumorigenesis in nasopharyngeal carcinoma.
    Li J; Hu C; Chao H; Zhang Y; Li Y; Hou J; Huang L
    J Cell Mol Med; 2021 Oct; 25(19):9183-9198. PubMed ID: 34469038
    [TBL] [Abstract][Full Text] [Related]  

  • 33. MicroRNA-106a-5p alleviated the resistance of cisplatin in lung cancer cells by targeting Jumonji domain containing 6.
    Ge X; Jiang Y; Hu X; Yu X
    Transpl Immunol; 2021 Dec; 69():101478. PubMed ID: 34607003
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Exosomes from drug-resistant breast cancer cells transmit chemoresistance by a horizontal transfer of microRNAs.
    Chen WX; Liu XM; Lv MM; Chen L; Zhao JH; Zhong SL; Ji MH; Hu Q; Luo Z; Wu JZ; Tang JH
    PLoS One; 2014; 9(4):e95240. PubMed ID: 24740415
    [TBL] [Abstract][Full Text] [Related]  

  • 35. MicroRNA-139-5p affects cisplatin sensitivity in human nasopharyngeal carcinoma cells by regulating the epithelial-to-mesenchymal transition.
    Shao Q; Zhang P; Ma Y; Lu Z; Meng J; Li H; Wang X; Chen D; Zhang M; Han Y; Liu H; Ma S
    Gene; 2018 Apr; 652():48-58. PubMed ID: 29427737
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Identification of upregulated exosomal miRNAs between A2780 and A2780/DDP human ovarian cancer cells by high-throughput sequencing.
    Wang H; Liu L; Liu Q; Zheng J; Zheng Q; Chen Y; Xia H; Wu Q; Sun Y
    J Ovarian Res; 2023 May; 16(1):94. PubMed ID: 37179363
    [TBL] [Abstract][Full Text] [Related]  

  • 37. LncRNA NORAD/miR-202-5p regulates the drug resistance of A549/DDP to cisplatin by targeting P-gp.
    Shen JG; Xu SN; Yin LG
    Gen Physiol Biophys; 2020 Sep; 39(5):481-489. PubMed ID: 33084601
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Depletion of circPDSS1 inhibits ITGA11 production to confer cisplatin sensitivity through miR-515-5p in gastric cancer.
    Wang Y; Tang S; Li L; Sun C; Liu Y; Zhao Y
    J Chemother; 2023 Oct; 35(6):514-526. PubMed ID: 36484486
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Long Noncoding RNA Plasmacytoma Variant Translocation 1 Regulates Cisplatin Resistance via miR-3619-5p/TBL1XR1 Axis in Gastric Cancer.
    Wu C; Hu Y; Ning Y; Zhao A; Zhang G; Yan L
    Cancer Biother Radiopharm; 2020 Dec; 35(10):741-752. PubMed ID: 32407172
    [No Abstract]   [Full Text] [Related]  

  • 40. MiR-219a-5p enhances cisplatin sensitivity of human non-small cell lung cancer by targeting FGF9.
    Rao C; Miao X; Zhao G; Zhang C; Shen H; Dong C; Yang M
    Biomed Pharmacother; 2019 Jun; 114():108662. PubMed ID: 30999114
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 80.